samedan logo
home > pmps > autumn 2021 > from delivery to dispensation
Pharmaceutical Manufacturing and Packing Sourcer

From Delivery to Dispensation

Drug development is evolving. Clinical trials are not only becoming larger in scale but more complex in nature. Biologics are superseding small molecule, high stability profile therapeutics – placing an onus on sponsors and CROs to develop effective strategies of maintaining strict temperature conditions and precise handling controls throughout a drug’s lifecycle.

The emergence of advanced cell and gene therapies is creating new demand for next-generation, ultra-low, cryogenic supply chain strategies. With the advanced therapy market becoming more competitive, and expected to grow significantly in the coming years, attention is being paid to the solutions and technologies available to store, process, and distribute the highly sensitive products. From vapour shippers and use of building management systems (to monitor vessels and environmental conditions) to strategies to improve efficiency of receiving, labelling, and distributing materials, while ensuring minimal time out of ultra-low temperature conditions. With such high-value investigational medicinal products (IMPs) leaving little margin for error, and with patient safety firmly in mind, recognition of the importance of creating end-toend temperature data visibility is also increasing.

Regulation is a key driver for sponsors and CROs to prioritise end-to-end data visibility. GDP places a regulatory requirement on sponsors to collect all temperature data to prove an IMP has maintained ideal storage conditions through each phase of the clinical supply chain. The guidelines also require that data are readily accessible, and that sponsors utilise a process for effectively investigating excursions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Sarah Smyth graduated from Queen’s University Belfast, Northern Ireland, with a BEd in Business Studies. After graduating, Sarah gained a wide range of experience working in the clinical diagnostics industry, especially around solutions regarding shipping temperature-sensitive products in challenging climates. In 2016, she joined Almac and has since worked with a large number of pharma and biotech companies initially in developing proposals to fulfil packaging and distribution needs, aiding in the successful delivery of a range of clinical trials. More recently, Sarah has worked closely with clients to understand the challenges they face with distributing temperature-sensitive drug products and advising on the best solutions to implement for efficient management of temperature data on a global scale

Print this page
Send to a friend
Privacy statement
News and Press Releases

Can Packaging Serialisation Be As Simple As 1,2,3?

For businesses that operate in the pharmaceutical and health categories, traceability, safety, and security are top priorities when designing packaging.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

Industry Events

Connect in Pharma

14-15 September 2022, Plaexpo, Geneva, Switzerland

The new event driving innovation for pharma and biopharma businesses, Connect in Pharma will unite key players in Pharmaceutical and Biopharmaceutical packaging and production in Geneva on 14 – 15 September 2022.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement